Xeris Biopharma HoldingsXERS
XERS
About: Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Employees: 394
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
263% more call options, than puts
Call options by funds: $857K | Put options by funds: $236K
182% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 11
88% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 32
22% more capital invested
Capital invested by funds: $182M [Q3] → $223M (+$40.4M) [Q4]
13% more funds holding
Funds holding: 143 [Q3] → 161 (+18) [Q4]
1.14% more ownership
Funds ownership: 42.9% [Q3] → 44.04% (+1.14%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
3%
downside
Avg. target
$6.10
48%
upside
High target
$8
95%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Piper Sandler David Amsellem 44% 1-year accuracy 14 / 32 met price target | 3%downside $4 | Neutral Reiterated | 7 Mar 2025 |
Leerink Partners Roanna Ruiz 25% 1-year accuracy 2 / 8 met price target | 46%upside $6 | Outperform Maintained | 7 Mar 2025 |
Craig-Hallum Chase Knickerbocker 35% 1-year accuracy 9 / 26 met price target | 58%upside $6.50 | Buy Maintained | 7 Mar 2025 |
HC Wainwright & Co. Oren Livnat 48% 1-year accuracy 24 / 50 met price target | 95%upside $8 | Buy Reiterated | 7 Mar 2025 |
Jefferies Glen Santangelo 45% 1-year accuracy 5 / 11 met price target | 46%upside $6 | Buy Reiterated | 29 Jan 2025 |
Financial journalist opinion
Neutral
Business Wire
3 weeks ago
Xeris Announces Changes to Its Board of Directors
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced changes to its board of directors. Ricki Fairley has resigned from the board in light of other commitments, effective immediately. The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy. In addition.
Positive
Zacks Investment Research
1 month ago
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?
Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Neutral
Business Wire
1 month ago
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its supplemental new drug application (sNDA) of Gvoke VialDx™ has received U.S Food and Drug Administration (FDA) approval for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tra.
Neutral
Seeking Alpha
1 month ago
Xeris Biopharma Holdings, Inc. (XERS) Q4 2024 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pieper - CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Oren Livnat - H.C. Wainwright Glen Santangelo - Jefferies David Amsellem - Piper Sandler Leland Gershell - Oppenheimer Mazahir Alimohamed - Leerink Partners Operator Good morning, and welcome to the Xeris Biopharma Fourth Quarter and Full Year 2024 Financial Results.
Positive
Zacks Investment Research
1 month ago
Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings
Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Negative
Zacks Investment Research
1 month ago
Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates
Xeris Biopharma (XERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.10 per share a year ago.
Neutral
Business Wire
1 month ago
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2024 and provides full-year 2025 financial guidance. “The Xeris team executed an exceptional 2024 with record revenue topping $203 million,” said John Shannon, Xeris' Chief Ex.
Neutral
Business Wire
1 month ago
Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full-year 2024 financial results and provide 2025 financial guidance before the open of the U.S. financial markets on Thursday, March 6, 2025. Management will host a conference call and webca.
Positive
Zacks Investment Research
1 month ago
Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Xeris Biopharma (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Business Wire
1 month ago
Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision and.
Charts implemented using Lightweight Charts™